NHS use of Incyte's anal cancer drug Zynyz backed by NICE

Natera and Incyte are collaborating on a Phase II trial (NCT07823322) for Incyte's immunotherapy INCA33890 in colorectal cancer. Natera's Signatera will monitor minimal residual disease. Natera will provide trial design and patient matching services. Both companies aim to address unmet needs in colorectal cancer treatment.

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.

Incyte's povorcitinib, an oral JAK1 inhibitor, met primary endpoints in phase 3 trials for hidradenitis suppurativa (HS), showing 40-42% HiSCR50 at week 12 vs. 29-30% for placebo. At week 54, HiSCR50 reached up to 71.4%. Incyte has submitted applications to the FDA and EMA. Dr. Martina Porter discusses the drug's potential to address unmet needs in HS treatment, offering a distinct mechanism from current biologics.

Natera (NTRA) and Incyte (INCY) are collaborating on a phase II colorectal cancer study. The trial will use Natera's Signatera test to guide treatment with Incyte's investigational immunotherapy INCA33890. Patients testing positive for minimal residual disease (MRD) post-treatment may be eligible. Natera will provide trial matching services.

Incyte Corp. (INCY) is advancing two cancer treatments, INCB161734 and INCA33890, into late-stage trials after early results showed promising responses in pancreatic and colorectal cancers. INCB161734, combined with chemotherapy, showed high response rates in pancreatic cancer, while INCA33890 demonstrated activity in colorectal cancer. The company plans Phase 3 trials with topline results expected in 2028 and 2029, respectively.

Incyte Corp. sued Granules India Ltd. for allegedly infringing five patents related to its blood cancer drug Jakafi XR. Incyte claims Granules filed an FDA application to sell a generic version before its patents expire. The case was filed in the US District Court for the Eastern District of Texas.